Waters, L., Assoumou, L., González-Cordón, A., Rusconi, S., Domingo, P., Gompels, M., de Wit, S., Raffi, F., Stephan, C., Masiá, M., Rockstroh, J., Katlama, C., Behrens, G. M. N., Moyle, G., Johnson, M., Fox, J., Stellbrink, H., Guaraldi, G., Florence, E., Esser, S., Gatell, J. M., Pozniak, A., Martínez, E., & , (2023). limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial. Clinical infectious diseases, 76, 861–870. http://access.bl.uk/ark:/81055/vdc_100179860478.0x00003c